[go: up one dir, main page]

CN1190351A - 把17－脱乙酰基诺孕酯单独或与雌激素结合给药的经皮贴片和方法 - Google Patents

把17－脱乙酰基诺孕酯单独或与雌激素结合给药的经皮贴片和方法 Download PDF

Info

Publication number
CN1190351A
CN1190351A CN96195390A CN96195390A CN1190351A CN 1190351 A CN1190351 A CN 1190351A CN 96195390 A CN96195390 A CN 96195390A CN 96195390 A CN96195390 A CN 96195390A CN 1190351 A CN1190351 A CN 1190351A
Authority
CN
China
Prior art keywords
paster
ngm
women
estrogen
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN96195390A
Other languages
English (en)
Other versions
CN1188189C (zh
Inventor
J·乔纳
J·奥德特
N·辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cygnus Inc
Original Assignee
Cygnus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27044166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1190351(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cygnus Inc filed Critical Cygnus Inc
Publication of CN1190351A publication Critical patent/CN1190351A/zh
Application granted granted Critical
Publication of CN1188189C publication Critical patent/CN1188189C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明涉及用于预防妇女排卵的组合物和方法,以及用于雌激素替代疗法的组合物和方法。该组合物是通过使用经皮贴片给药的。该贴片将把17－脱乙酰基诺孕酯单独或与雌激素如炔雌醇结合给药于妇女。

Description

把17-脱乙酰基诺孕酯单独或 与雌激素结合给药的经皮贴片和方法
本发明涉及药物的经皮释放，更具体地说，它涉及把17-脱乙酰基诺孕酯单独或与雌激素，特别是炔雌醇结合经皮给药的贴片和方法。
诺孕酯(Ngm)和炔雌醇(EE)的组合物口服给妇女用作避孕药。Bringer J.，Am.J.Obstet.Gynecol.(1992)166：1969-77.McGuire，J.C.等，Am.J.Obstet.Gynecol.(1990)163：2127-2131中暗示口服的Ngm代谢为17-脱乙酰基诺孕酯(17-d-Ngm)、3-酮诺孕酯和左炔诺孕酮(Lng)，并且这些代谢产物对口服药物的药理反应起着主要作用。
Chien等的美国专利4,906,169描述了把雌激素类和孕激素类共同释放给妇女避孕的经皮贴片。其中提到EE作为可以从该贴片给药的雌激素而且提到Ngm和Lng作为可以给药的孕激素。
申请人没有看到描述有把17-d-Ngm单独或与任何雌激素通过经皮或其他给药途径给药的任何现有技术。
本发明提供了通过给妇女使用有效量的17-脱乙酰基诺孕酯来预防排卵或提供激素替代疗法的组合物和方法。一方面是把17-脱乙酰基诺孕酯与抑制排卵量的雌激素联合用药给妇女。该组合物优选经皮给药。
所以，本发明的一方面是预防妇女排卵的经皮贴片，它包括：背衬层；和，位于该背衬下面的基质层，该基质层包括17-d-Ngm和压敏粘合剂的混合物该贴片适合于对妇女皮肤的扩散传递并将抑制排卵量的17-d-Ngm用药到该皮肤上。
本发明的另一方面是把17-d-Ngm与雌激素给药于妇女的经皮贴片，它包括：背衬；和位于该背衬下面的基质层，该基质层包括17-d-Ngm、雌激素和压敏粘合剂的混合物，该贴片适合于对妇女皮肤的扩散传递，及把抑制排卵量的17-d-Ngm和雌激素通过皮肤给药于妇女。这些贴片也能用来提供激素替代疗法。
本发明提供了预防妇女排卵的组合物和方法，它包括给予抑制排卵量的17-脱乙酰基诺孕酯。有效量大约为150到350μg/天并优选175到300μg/天的17-脱乙酰基诺孕酯。一方面是把17-脱乙酰基诺孕酯与抑制排卵量的雌激素如炔雌醇联合用药。有效量大约为150到350μg/天并优选175到300μg/天的17-脱乙酰基诺孕酯和10到35μg/天的炔雌醇。
本发明的经皮贴片提供给妇女避孕。它们也适合于激素替代疗法。
该贴片为的是在较长的时期，一般1-7天并优选7天把17-d-NRm，任选雌激素连续释放到皮肤上。
当该贴片用于避孕时，一般在月经循环的第5天放在皮肤上，按需要可到完全消耗的第21天替换。例如，对7天的贴片来说，在21天期间将需要3片贴片来释放药物。如果需要的话，在连续的月经循环第5天后可用一种安慰剂的贴片。对每次月经循环重复这种方法。
17-d-Ngm和雌激素都能抑制排卵，虽然通过不同途径。17-d-Ngm抑制黄体化激素(LH)，而雌激素的主要作用是抑制刺激卵泡激素(FSH)的分泌。所以，按照本发明当把17-d-Ngm与雌激素联合给药时，通过抑制排卵刺激物和/或通过抑制卵泡的生长来预防排卵。相对于母体化合物(Ngm)或其代谢物来说，人们认为17-d-Ngm给药的优点在于17-d-Ngm对雄激素活性方面只有很小或没有抑制。
17-d-Ngm抑制排卵的有效剂量一般是在约150到350μg/天，优选175到300μg/天和更优选175到250μg/天的范围。本发明的贴片一般有10到50cm2的基底表面区(即与皮肤扩散接触的区域)。雌激素抑制排卵的有效剂量一般取决于联合用药的特定雌激素。例如，当雌激素是炔雌醇时，剂量一般至少是10μg/天，优选10到35μg/天和更优选大约20μg/天。该贴片将含有足够量的17-d-Ngm和，当存在时，雌激素来给消耗的贴片提供这种每日剂量。一般这种剂量大约为20μg/天到200μg/天，优选30到150μg/天的炔雌醇。
本发明的贴片是基质或单片型层状结构。这类经皮贴片在本领域是熟知的。它们包括与压敏粘合剂和背衬混合的药物基质层。该基质作为药物库并通过它把该贴片固定在皮肤上。使用前，该贴片也包括防水的衬里层。
背衬是不渗透药物和基质中的其他组分的并限定了该贴片的上表面。它可以是由聚合物的单层或膜组成，或是一个或多个聚合物层和金属薄层的层制品。适用于制作背衬薄膜的聚合物的例子有聚氯乙烯、聚偏二氯乙烯、聚烯烃类如乙烯-乙酸乙烯酯共聚物、聚乙烯和聚丙烯、聚氨酯以及聚酯类如聚对苯二甲酸乙二醇酯。
基质中的压敏粘合剂一般是聚丙烯酸酯、聚硅氧烷或聚异丁烯(PIB)溶液。这类压敏粘合剂在经皮领域中是熟知的。例如，参见《压敏粘合技术手册》第二版(1989)Van Nostrand，Reinhold。液状压敏聚丙烯酸酯粘合剂是通过在有机溶液中共聚一种或多种丙烯酸酯单体(把“丙烯酸酯”规定为包括丙烯酸酯和甲基丙烯酸酯两种)、一种或多种改性单体和一种或多种含有功能基团的单体得到的。用于制备这些聚合物的丙烯酸酯单体一般是4-17个碳原子的烷基丙烯酸酯，优选丙烯酸2-乙基已基酯、丙烯酸丁酯和甲基丙烯酸异辛酯。改良单体一般包括能改变聚合物的Tg的单体。用于本发明目的的这类单体是乙酸乙烯酯、丙烯酸乙酯和甲基丙烯酸乙酯及甲基丙烯酸甲酯，含有功能性基团的单体提供了可以交联的部位。这些单体的功能基团优选为羧基、羟基或其混合物。提供这类基团的单体有丙烯酸、甲基丙烯酸和含有羟基的单体如丙烯酸羟基乙酯。最好用交联剂交联该聚丙烯酸酯粘合剂来改善它们的物理性能(如蠕变和剪切阻力)。由于交联程度越高将会有害地影响该共聚物的粘合性能，所以交联密度应当较低。在美国专利5,393,529中公开了交联剂的例子。溶液型聚丙烯酸酯压敏粘合剂可从3M得到市售的商标为如GELVATM和DURO-TAKTM的产品。
聚异丁烯粘合剂是高分子量(HMW)PIB和低分子量(LMW)PIB的混合物。在现有技术中如PCT/US91/02516中描述了这类混合物。HMW PIB的分子量通常在大约700,000到2,000,000Da的范围，而LMW PIB的分子量一般在大约35,000到60,000Da范围内。本文所指的分子量是重均分子量。在该粘合剂中HMW PIB与DMW PIB的重量比一般为1∶1到1∶10。PIB粘合剂一般也包括一种增粘剂如聚丁烯油和高Tg，低分子量的脂，族树脂如从Exxon Chemical得到的ESCOREZTM树脂。聚异丁烯聚合物可从Exxon Chemical得到市售的商标为VISTANEX的产品。
在形成基质中所用的聚硅氧烷粘合剂一般是高分子量的聚二甲基硅氧烷或聚二甲基二苯基硅氧烷。美国专利5,232,702、4,906,169和4,951,622中描述了在经皮贴片中可用的聚硅氧烷粘合剂的配方。
在基质中可与17-d-Ngm结合的雌激素包括17-J-雌二醇及其酯如戊酸雌二醇酯、环戊丙酸雌二醇酯、乙酸雌二醇、苯甲酸雌二醇酯和庚酸雌二醇酯(EE)。对用于结合17-d-Ngm来说，庚酸雌二醇酯(EE)是优选的雌激素。EE/17-d-Ngm结合物可以有益地影响代谢参数从而提高血浆高密度脂蛋白和降低血浆中低密度脂蛋白/高密度脂蛋白比。
除了压敏粘合剂、17-d-Ngm和任选的雌激素外，该基质一般包括足量的渗透促进剂来增加17-d-Ngm和雌激素穿过皮肤的渗透性并提供上述范围内的助熔剂。可包括在基质中的皮肤渗透促进剂的例子在美国专利5,059,426、4,973,468、4,906,463和4,906,169中进行了描述，并且包括但不限定为C12到C18脂族醇的乳酸酯、乳酸十二烷基酯、油酸或PGML。包括在基质中的渗透促进剂的量一般取决于所用的特殊促进剂。在多数情况中，该促进剂占该基质重量的1到20％的范围。
根据所用的特殊粘合剂，该基质可以包括其它添加剂。例如可以包括抑制药物结晶的物质如聚乙烯吡咯烷酮(PVP)、改善磨损周期的亲水剂或改善该基质的物理(如冷流动)或粘合剂(如粘着性、粘结强度)特性的添加剂。
对激素替代疗法来说，也可以使用上述贴片。当用于提供激素替代疗法时，构建基质以提供用于该目的的有效量的17-d-Ngm和雌激素。一般，提供大约150到350μg/天，优选大约175到300μg/天的17-d-Ngm及共同给药的大约5到45μg/天优选大约10到35μg/天的炔雌醇来构建基质及其贴片。在另一个实施方案中，该贴片将提供约200到350μg/天，优选大约175到300μg/天的17-d-Ngm及共同给药的大约20到175μg/天和优选大约30到150μg/天的17-β-雌二醇。对治疗来说，贴片可用7天然后用新贴片(7天)替换。
用经皮贴片领域中已知的步骤可以制备本发明的贴片。该步骤一般包括配制基质(即混合粘合剂、药物、渗透促进剂和添加剂，如果必要的话)，把基质充填到背衬或释放垫层上，从该基质中除去溶剂并应用背衬/释放垫层。正如本领域普通技术人员所显而易见的，能够把其中分散有有效量药物的基质组合物搀入各种经皮结构中，所以申请人没有限定在下列举例的实施方案。
下列实施例进一步详细说明本发明。这些实施例不是以任何方式限定本发明。除非另有说明，所述的百分比按重量计。
                         实施例实施例1
Duro-Tak87-2287是从National Starch and Chemical Co.得到的聚丙烯酸酯粘合剂的溶液。它的单体组分为：乙酸乙烯酯、丙烯酸2-乙基己基酯、丙烯酸羟乙基酯和甲基丙烯酸缩水甘油酯。它不包括交联剂。它以50％固体的乙酸乙酯溶液得到。
配制Duro-Tak 87-2287、0.26％乙酰丙酮酸铝交联剂、6％的17-d-Ngm、1％EE和各种渗透促进剂的混合物。在3M 1022背衬上固化这些混合物并铸成100微米厚(湿的)层，干燥。按照U.S.5,252,334第7栏中所描述的，在所得到的组件上进行皮肤通量试验。用HPLC测定17-d-Ngm和EE。将记有Diedoarray检测器的Perkin ElmerHPLC系统分别设定在245nm和215nm来测定17-d-Ngm和EE。流动相是55％的水、45％的乙腈，流速为1.0ml/分钟。对17-d-Ngm和EE来说，保留时间为4.5和3.0分钟。下表1显示了配方和流量试验的结果。
               表1
         流量(ug/cm2/hr)配方         17-d-Ngm         EE2％TG+4％OL     0.30±0.04    0.061±0.0072％TG+10％ML    0.39±0.03    0.076±0.0052％TG+4％PGML   0.29±0.06    0.0571±0.0093％TG           0.24±0.06    0.043±0.0114％TG+15％ML    0.38±0.001   0.072±0.002TG＝硫代甘油    OL＝油酸ML＝月桂酸甲酯  PGML＝单月桂酸丙二醇酯实施例2
硅氧烷4202是从Dow Corning得到的一种聚二甲基硅氧烷粘合剂。把它与17-d-Ngm、EE、7％PVP(从BASF得到的K30，溶于正丙醇中)和各种促进剂混合。在3M 1022聚酯背衬上将这些混合物制成100微米的厚层(湿的)并干燥。如实施例1所述的所得到的组件上进行皮肤流量试验。下表2报道了该配方的详细情况和流量试验的结果。
                        表2配方                                         流量(μg/m2/小时)％17-d-Ngm   ％EE     促进剂               17-d-Ngm         EE
4        0.5    5％ML+1％TG           0.65±0.09    0.069±0.007
6        0.5    5％ML+1％TG           0.60±0.04    0.043±0.004
6        0.5    14％PGML              0.48±0.04    0.070±0.01
6        0.5    14％(TC；PGML；80∶20)0.58±0.05    0.062±0.01*4       0.5    4％TG+5％ML           0.64±0.01    0.078±0.01
4        0.5    2％ML                 0.51±0.08    0.074±0.008
2        0.5    2％TG+2％ML           0.71±0.09    0.18±0.02*包括14％PVP而不是7％PVP。TC＝透皮醇(Transcutanol)实施例3
在硅氧烷粘合剂-17-d-Ngm/EE贴片上用两种类型的PVP进行对比研究：一种是从BASF得到的可溶性低分子量的PVP定义为PVP-K30和一种是从BASF得到的不溶性交联微化的PVP定义为PVP-CLM。
把PVP-K30溶于无水乙醇中。制备17-d-Ngm、EE和PVP-K30的混合物，然后再加入硅氧烷4202和月桂酸甲酯。把该混合物搅拌过夜。把混合物涂覆在3M1022衬垫上厚度为15mil(湿的)并在700℃干燥40分钟。
可得到PVP-CLM的微粉化的固体。把硅氧烷4202和PVP-CLM混合在一起，然后加入月桂酸甲酯、EE、17-d-Ngm和乙醇。搅拌混合物过夜并如上所述在3M1022衬垫上涂覆和干燥。
如实施例1所述在上述组件上进行皮肤通量试验。下列表3报道了这些配方的内容和皮肤通量试验的结果。
                     表3
                                   通量(μg/cm2/hr)
     配方                     17-d-Ngm            EE0.1％EE，1％17-d-Ngm，5％ML，    0.49±0.02      0.05±0.0027％PVP-CLM，86.9％硅氧烷0.1％EE，1％17-d-Ngm，5％ML，    0.37±0.07      0.04±0.0087％PVP-K30，86.9％硅氧烷实施例4
把VISTANEX L100、Vistanex LM-MSLC和聚丁烯(IndopolH1900)溶于己烷中来制备PIB溶液。制备PVP-CLM、17-d-Ngm、EE和各种促进剂的乙醇/乙酸乙酯悬浮液。把PIB溶液加入药物悬浮液中并把所得到的混合物完全混合。在释放衬垫上涂覆10mil厚(温的)的混合物并在70℃干燥40分钟。把Saranex 2015背材用薄板覆盖在组件上。如实施例1所述在上述组件上进行皮肤通量试验。下列表3报道了这些集合的内容和皮肤通量试验的结果。
                             表4
                                                                   通量(μg/cm2/hr)PIB*   ％EE  ％17-d-Ngm    ％PVP-CLM    ％促进剂％               17-d-Ngm         EE1∶5∶4    0.3    4.0           20        15.山梨酸二丁酯          0.23±0.02    0.06±0.0051∶5∶4    0.2    1.0           20        5.AMIFAT                 0.32±0.02    0.05±0.0041∶5∶4    0.2    4.0           20        5.月桂酰N，N-二甲基酰胺  0.33±0.02    0.04±0.0012∶4∶4    0.3    4.0           20        20.月桂酸丙酯            0.35±0.09    0.06±0.0021∶5∶4    0.2    2.0           20        5.月桂酰二乙醇胺         0.40±0.05    0.06±0.0011∶5∶4    0.3    4.0           20        15.棕榈酸异丙酯          0.44±0.06    0.07±0.0011∶5∶4    0.3    4.0           20        15.油酸乙酯              0.46±0.06    0.10±0.0011∶5∶4    0.3    4.0           20        8.PGIS                   0.48±0.04    0.10±0.0011∶5∶4    0.2    2.0           20        3.油酸                   0.60±0.11    0.06±0.0021∶5∶4    0.2    3.0           20        3.油酸                   0.60±0.24    0.04±0.0021∶5∶4    0.2    2.0           20        10.PGML                  0.59±0.05    0.09±0.0011∶5∶4    0.2    3.0           20        10.PGML                  0.67±0.07    0.07±0.0011∶5∶4    0.3    4.0           20        8/3.PGML/油酸            0.79±0.04    0.14±0.0011∶5∶4    0.2    2.0           20        10/05.PGML/油酸          0.68±0.09    0.10±0.001*Vistanex L100∶Vistanex LM-MS-LC：聚丁烯的重量比AMIFAT来自甘油、油酸和2-吡咯烷酮-5-甲酸。PGIS＝异硬脂酸丙二醇酯。*Vistanex L100∶Vistanex LM-MS-LC：聚丁烯的重量比AMIFAT来自甘油、油酸和2-吡咯烷酮-5-甲酸。PGIS＝异硬脂酸丙二醇酯。实施例5
如下制备适合于激素替代疗法的组合物和基质。把2％17β-雌二醇、2％17-去乙酰基诺孕酯、20％PVP-CLM和76％PIB粘合剂(1∶5∶2.5∶1.5Vistanex L100∶Vistanex LM-MS-LC∶聚丁烯∶Zonester 85FG)溶于己烷、乙酸乙酯和乙醇的混合物中。把它涂覆到聚酯释放衬垫上并在70℃干燥45分钟。在通量试验之前使用聚酯背材。如实施例1所描述的进行通量试验。
               表5
甾体                   通量(μg/cm2/hr)17-d-Ngm                       0.1017-β-雌二醇                   0.20实施例6
如下制备具有由PIB粘合剂、PVP-CLM、乳酸月桂酯或肉豆蔻酯、17-d-Ngm和EE组成的基质的经皮贴片：
把17-d-Ngm和EE溶于乙酸乙酯并向该溶液中加入PVP-CL和乳酸月桂酯或乳酸肉豆蔻酯(从新泽西Belleviile的ISP VanDYK得到)。在剧烈混合下把PIB粘合剂(1∶5∶4Vistanex L100∶Vistanex LM-MS-LC∶Indopol H 1900)的己烷溶液加入甾体溶液中。把10％PVP-CLM重量的的N-丙醇缓慢加入最终组合物中。把该混合物涂覆在释放衬垫上并在70℃干燥40分钟。干燥的基质重量为7.5mg/cm2。把基质释放衬垫组件用薄板覆盖在聚酯(Scotchpak 1012)背衬上。把其它组件用薄板覆盖在非纺织的聚酯层(Remay 2250)。把释放层从背衬组件上取下并把它涂到非纺织层组件而得到5层由背衬/粘合剂基质/非纺织/粘合剂基质/释放衬垫组成的层。
如实施例1中所述在这些贴片上进行皮肤流通量试验。下表5报道了这些贴片的内容和通量试验的结果。
                 表6基质配方       皮肤渗透性    17-d-Ngm通量      EE通量
                        (μg/cm2/小时) (μg/cm2/小时)72.85％PIB       低             0.23             0.0220％PVP-CLM      中等           0.45             0.050.15％EE         高             0.82             0.085％乳酸月桂酯70.8％PIB        低             0.20             0.0320％PVP-CLM      中等           0.55             0.080.2％EE2％17-d-Ngm7％乳酸月桂酯72.8％PIB        -              0.64             0.0920％PVP-CLM0.2％EE2％17-d-Ngm5％乳酸肉豆蔻酯
对实施本发明来说，经皮贴片领域普通技术人员对上述模式进行的显而易见的改良也包括在下列权利要求的范围中。

Claims (38)

1.预防妇女排卵的经皮贴片，它包括：(a)背衬；和(b)基质层，位于该背衬的下面，该基质层包括17-脱乙酰基诺孕酯和一种压敏粘合剂的混合物并适合于对妇女皮肤的扩散传递，以及适于给予抑制排卵量的17-脱乙酰基诺孕酯。
2.根据权利要求1的贴片，其中所述量是175/300μg/天。
3.根据权利要求1的贴片，其中压敏粘合剂是聚丙烯酸酯、聚硅氧烷或聚异丁烯的溶液。
4.根据权利要求1的贴片，其中基质层包括皮肤渗透促进剂。
5.根据权利要求4的贴片，其中渗透促进剂主要选自C12到C18脂族醇的乳酸酯、油酸和PGML。
6.根据权利要求5的贴片，其中渗透促进剂是乳酸十二烷基酯。
7.预防妇女排卵的经皮贴片，它包括：(a)背衬；和(b)基质层，其位于该背衬的下面，该基质层包括17-脱乙酰基诺孕酯、雌激素和压敏粘合剂的混合物并适合于对妇女皮肤的扩散传递，以及适于将抑制排卵量的17-脱乙酰基诺孕酯和雌激素共同给药于妇女。
8.根据权利要求7的贴片，其中压敏粘合剂是聚丙烯酸酯、聚硅氧烷或聚异丁烯的溶液。
9.根据权利要求8的贴片，其中基质层包括皮肤渗透促进剂。
10.根据权利要求9的贴片，其中雌激素是雌二醇。
11.根据权利要求10的贴片，其中雌二醇是炔雌醇或17-β-雌二醇。
12.根据权利要求11的贴片，其中雌二醇是炔雌醇。
13.根据权利要求12的贴片，其中所述量是175到300μg/天的17-脱乙酰基诺孕酯和10到35μg/天的炔雌醇。
14.根据权利要求11的贴片，其中雌二醇是17-β-雌二醇。
15.根据权利要求14的贴片，其中所述量是175到300μg/天的17-脱乙酰基诺孕酯和30到150μg/天的17-β-雌二醇。
16.根据权利要求11的贴片，其中渗透促进剂主要选自C12到C18脂族醇的乳酸酯、油酸和PGML。
17.根据权利要求16的贴片，其中渗透促进剂是乳酸十二烷基酯。
18.预防妇女排卵的方法，它包括将抑制排卵量的17-脱乙酰基诺孕酯经皮给药于妇女。
19.根据权利要求18的方法，其中所述量是175到300μg/天。
20.预防妇女排卵的方法，它包括将抑制排卵量的17-脱乙酰基诺孕酯和雌激素经皮给药于妇女。
21.根据权利要求20的方法，其中雌激素是炔雌醇。
22.根据权利要求21方法，其中的用量是175到300μg/天的17-脱乙酰基诺孕酯和10到35μg/天的炔雌醇。
23.给妇女提供激素替代疗法的经皮贴片，它包括：(a)背衬；和(b)基质层，位于该背衬的下面，该基质层包括17-脱乙酰基诺孕酯、雌激素和压敏粘合剂的混合物并适合于对妇女皮肤的扩散传递，以及适于将抑制排卵量的17-脱乙酰基诺孕酯和雌激素经皮共同给药于妇女。
24.根据权利要求23的贴片，其中压敏粘合剂是聚丙烯酸酯、聚硅氧烷或聚异丁烯的溶液。
25.根据权利要求24的贴片，其中基质层包括皮肤渗透促进剂。
26.根据权利要求25的贴片，其中雌激素是雌二醇。
27.根据权利要求26的贴片，其中雌二醇是炔雌醇或17-β-雌二醇。
28.根据权利要求27的贴片，其中雌二醇是炔雌醇。
29.根据权利要求28的贴片，其中17-脱乙酰基诺孕酯的用量是175到300μg/天而炔雌醇的用量是10到35μg/天。
30.根据权利要求27的贴片，其中雌二醇是17-β-雌二醇。
31.根据权利要求30的贴片，其中17-脱乙酰基诺孕酯的用量是175到300μg/天而17-β-雌二醇的用量是30到150μg/天。
32.根据权利要求27的贴片，其中渗透促进剂主要选自C12到C18脂族醇的乳酸酯、油酸和PGML。
33.根据权利要求32的贴片，其中渗透促进剂是乳酸十二烷基酯。
34.预防妇女排卵的方法，它包括将抑制排卵量的17-脱乙酰基诺孕酯经皮给药于妇女。
35.根据权利要求34的方法，其中17-脱乙酰基诺孕酯的用量约是175到300μg/天。
36.预防妇女排卵的方法，它包括将抑制排卵量的17-脱乙酰基诺孕酯和雌激素经皮给药于妇女。
37.根据权利要求34的方法，其中雌激素是炔雌醇。
38.根据权利要求34的方法，其中17-脱乙酰基诺孕酯的用量约是175到300μg/天而炔雌醇的用量约是10到35μg/天。
CNB96195390XA 1995-06-07 1996-06-06 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途 Expired - Lifetime CN1188189C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47353195A 1995-06-07 1995-06-07
US08/473,531 1995-06-07
US51726395A 1995-08-21 1995-08-21
US08/517,263 1995-08-21

Publications (2)

Publication Number Publication Date
CN1190351A true CN1190351A (zh) 1998-08-12
CN1188189C CN1188189C (zh) 2005-02-09

Family

ID=27044166

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB96195390XA Expired - Lifetime CN1188189C (zh) 1995-06-07 1996-06-06 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途

Country Status (22)

Country Link
US (3) US5876746A (zh)
EP (1) EP0836506B2 (zh)
JP (2) JP3534775B2 (zh)
KR (1) KR100301226B1 (zh)
CN (1) CN1188189C (zh)
AT (1) ATE229828T1 (zh)
AU (1) AU703593B2 (zh)
CA (1) CA2222133C (zh)
CZ (1) CZ292151B6 (zh)
DE (1) DE69625483T3 (zh)
DK (1) DK0836506T4 (zh)
ES (1) ES2190472T5 (zh)
HU (1) HU228434B1 (zh)
IL (1) IL122432A (zh)
MX (1) MX9709666A (zh)
NO (1) NO316308B1 (zh)
NZ (1) NZ311304A (zh)
PL (1) PL181582B1 (zh)
PT (1) PT836506E (zh)
RU (1) RU2177311C2 (zh)
UA (1) UA48973C2 (zh)
WO (1) WO1996040355A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1318032C (zh) * 2005-01-24 2007-05-30 浙江大学 炔雌醇透皮吸收贴片
CN100355771C (zh) * 2003-06-30 2007-12-19 匈牙利吉瑞大药厂 合成高纯度D－(17α)－13－乙基－17－羟基－18,19－二去甲孕－4－烯－20－炔－3－酮－肟的方法
CN105416940A (zh) * 2015-11-30 2016-03-23 芜湖成德龙过滤设备有限公司 便于清洁的货架

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE19549264A1 (de) * 1995-12-23 1997-06-26 Schering Ag Verfahren und Kit zur Kontrazeption
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US5939477A (en) * 1998-02-02 1999-08-17 Dow Corning Corporation Silicone pressure sensitive adhesive composition containing functionalized polyisobutylene
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19834007C1 (de) * 1998-07-29 2000-02-24 Lohmann Therapie Syst Lts Estradiolhaltiges Pflaster zur transdermalen Applikation von Hormonen und seine Verwendung
PT1666026E (pt) † 1999-02-08 2012-03-15 Intarcia Therapeutics Inc Veículos viscosos não aquosos biocompatíveis monofásicos e métodos para a preparação dos mesmos
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6417227B1 (en) 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
AU5766400A (en) * 1999-06-25 2001-01-31 Jonalee M. Schmidt Hairpiece and method for attaching same
DE19943317C1 (de) 1999-09-10 2001-03-15 Lohmann Therapie Syst Lts Kunststofffolien, insbesondere für die Verwendung in einem dermalen oder transdermalen therapeutischen System und Verfahren zu ihrer Herstellung
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
PT1242012E (pt) * 1999-11-24 2010-03-31 Agile Therapeutics Inc Sistema e processo melhorado de libertação transdérmica de contraceptivo
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US7223418B2 (en) * 2000-03-07 2007-05-29 Tiejin Limited Stretchable patch
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US7235397B1 (en) 2000-04-14 2007-06-26 Gensys, Inc. Methods and compositions for culturing spirochete and treating spirochetal diseases
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
JPWO2002032431A1 (ja) * 2000-10-16 2004-02-26 久光製薬株式会社 外用剤組成物
WO2002045701A2 (en) * 2000-12-05 2002-06-13 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
AU2002316053A1 (en) * 2001-05-01 2002-11-11 A.V. Topchiev Institute Of Petrochemical Synthesis Two-phase, water-absorbent bioadhesive composition
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
WO2002087645A1 (en) * 2001-05-01 2002-11-07 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
WO2003024450A1 (en) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
AU2002340232A1 (en) * 2001-10-17 2003-04-28 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
WO2003063927A2 (en) * 2001-11-16 2003-08-07 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
AU2002366796A1 (en) * 2001-12-19 2003-07-09 Eisai Co. Ltd Methods using proton pump inhibitors
CN1652796A (zh) * 2002-03-11 2005-08-10 詹森药业有限公司 使用雌激素和抑制硫酸酯酶的孕激素的长周期避孕给药方案
CA2478206A1 (en) * 2002-03-11 2003-09-25 Patrick Michel Caubel Sulfatase inhibiting continuous progestogen contraceptive regimens
JP2005519961A (ja) * 2002-03-11 2005-07-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 継続的スルファターゼ阻害プロゲストゲンホルモン補充療法
US20030219471A1 (en) * 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
US7223386B2 (en) * 2002-03-11 2007-05-29 Dow Corning Corporation Preparations for topical skin use and treatment
US20030225047A1 (en) * 2002-03-11 2003-12-04 Caubel Patrick Michel Sulfatase inhibiting progestogen-only contraceptive regimens
US20040142914A1 (en) * 2002-03-11 2004-07-22 Friedman Andrew Joseph Extended transdermal contraceptive regimens
WO2003095623A2 (en) * 2002-05-10 2003-11-20 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
WO2003097011A1 (en) * 2002-05-17 2003-11-27 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
NZ538342A (en) * 2002-08-28 2007-08-31 Robert Casper Estrogen replacement regimen
PT1426049E (pt) * 2002-12-02 2005-09-30 Sanol Arznei Schwarz Gmbh Administracao iontoforetica de rotigotina para o tratamento da doenca de parkinson
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
SI1594483T1 (sl) 2003-02-21 2006-12-31 Schering Ag UV-stabilni transdermalni terapevtski obliz
US20060058336A1 (en) * 2003-02-27 2006-03-16 Shigetada Nakanishi Pharmaceutical composition for treatment of drug dependence
US7576226B2 (en) 2003-06-30 2009-08-18 Richter Gedeon Vegyeszeti Gyar Rt. Process of making isomers of norelgestromin and methods using the same
HUP0301981A2 (hu) * 2003-06-30 2005-04-28 Richter Gedeon Vegyészeti Gyár Rt. Tiszta d-(17alfa)-13-etil-17-hidroxi-18,19-dinor-pregn-4-én-20-in-3-on-3E- és 3Z-oxim izomerek, valamint eljárás az izomer keverékek és a tiszta izomerek előállítására
JP2007502831A (ja) * 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
EP1667643A4 (en) * 2003-08-28 2008-03-05 Nitromed Inc NITROSIS AND NITROSYL CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
NZ548091A (en) * 2003-12-12 2009-12-24 Bayer Schering Pharma Ag Transdermal delivery system of hormones without penetration enhancers
US20090131342A1 (en) * 2004-01-22 2009-05-21 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
US20050191338A1 (en) * 2004-01-30 2005-09-01 Lifeng Kang Transdermal drug delivery composition comprising a small molecule gel and process for the preparation thereof
KR20070007299A (ko) 2004-01-30 2007-01-15 코리움 인터네셔널, 인크. 활성제의 전달을 위한 급속 용해 필름
JP5220406B2 (ja) 2004-04-28 2013-06-26 ブリガム・ヤング・ユニバーシティ 皮膚疾患を処置するためのエクオールの使用
DE102004028284A1 (de) * 2004-06-11 2006-01-05 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System auf Basis eines Schmelzklebstoffs zur Anwendung von Norelgestromin
MX2007001512A (es) * 2004-08-05 2007-04-20 Corium Int Inc Composicion adhesiva.
JP4824963B2 (ja) * 2004-08-12 2011-11-30 日東電工株式会社 貼付材及び貼付製剤
JP4745747B2 (ja) * 2004-08-12 2011-08-10 日東電工株式会社 フェンタニル含有貼付製剤
US20060121102A1 (en) * 2004-09-27 2006-06-08 Chia-Ming Chiang Transdermal systems for the delivery of estrogens and progestins
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
DK2216018T3 (da) 2004-10-21 2012-07-02 Durect Corp Transdermale leveringssystemer
CA2595579A1 (en) * 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CA2597422A1 (en) * 2005-02-16 2007-08-02 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
CA2597463A1 (en) * 2005-02-28 2006-09-08 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
US20090274747A1 (en) * 2005-02-28 2009-11-05 Takashi Yasukochi Pressure-Sensitive Adhesive Base and Medical Adhesive Patch Including the Pressure-Sensitive Adhesive Base
CA2597444A1 (en) * 2005-03-09 2006-09-21 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
KR20080007233A (ko) 2005-04-04 2008-01-17 에자이 가부시키가이샤 두통용 디히드로피리딘 화합물 및 조성물
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
US20060253963A1 (en) * 2005-05-10 2006-11-16 Limbaugh John M Body keep
WO2006127591A2 (en) * 2005-05-23 2006-11-30 Nitromed, Inc. Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
US7874489B2 (en) * 2005-06-20 2011-01-25 Authentiform Technologies, Llc Product authentication
WO2007002009A2 (en) * 2005-06-20 2007-01-04 Johnson & Johnson Product authentication
US8247018B2 (en) * 2005-06-20 2012-08-21 Authentiform Technologies, Llc Methods for quality control
WO2007011763A2 (en) * 2005-07-15 2007-01-25 3M Innovative Properties Company Adhesive sheet and methods of use thereof
EP1915157A4 (en) * 2005-08-02 2010-09-01 Nicox Sa NICKEL OXYGENIZING ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND USE PROCESSES
US9056061B2 (en) * 2005-09-23 2015-06-16 Alza Corporation Transdermal nicotine salt delivery system
WO2007041681A2 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. Methods for treating respiratory disorders
US20090192128A1 (en) * 2005-10-04 2009-07-30 Nitromed Inc. Genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism
PL2450041T3 (pl) 2005-10-12 2019-02-28 Unimed Pharmaceuticals, Llc Ulepszony żel zawierający testosteron do zastosowania do leczenia hipogonadyzmu
EP1954685A4 (en) * 2005-11-16 2009-11-11 Nitromed Inc FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
WO2007075541A2 (en) * 2005-12-20 2007-07-05 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
WO2007075542A2 (en) * 2005-12-22 2007-07-05 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
US20090306027A1 (en) * 2006-04-10 2009-12-10 Nitomed, Inc. Genetic risk assessment in heart failure: impact of the genetic variation of g-protein beta 3 subunit polymorphism
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
WO2008020028A1 (en) 2006-08-16 2008-02-21 Action Medicines, S.L. 2,5 dihydroxybenzene compounds for the treatment of rosacea
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
WO2008067409A2 (en) * 2006-11-28 2008-06-05 Polyplus Battery Company Protected lithium electrodes for electro-transport drug delivery
EP2098235B1 (en) * 2006-12-01 2013-08-21 Nitto Denko Corporation Method for prevention of discoloration with time of donepezil-containing skin adhesive preparation
CN101605546B (zh) * 2006-12-01 2011-12-14 日东电工株式会社 抑制含有多奈哌齐的贴剂的经时变色的方法
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
CN101715340A (zh) 2007-04-23 2010-05-26 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
JP2010524844A (ja) * 2007-04-26 2010-07-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 認知症のためのシンナミド化合物
DE102007020799A1 (de) 2007-05-03 2008-11-06 Novosis Ag Transdermales therapeutisches System mit Remifentanil
US20090005824A1 (en) * 2007-06-29 2009-01-01 Polyplus Battery Company Electrotransport devices, methods and drug electrode assemblies
JP5192296B2 (ja) * 2007-07-05 2013-05-08 日東電工株式会社 貼付剤および貼付製剤
US20100178323A1 (en) 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
US20090069740A1 (en) * 2007-09-07 2009-03-12 Polyplus Battery Company Protected donor electrodes for electro-transport drug delivery
JP5209433B2 (ja) * 2007-10-19 2013-06-12 日東電工株式会社 貼付製剤
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
BRPI0912099A2 (pt) * 2008-05-30 2015-10-06 Eisai R&D Man Co Ltd preparação percutaneamente absorvível
CN102014905B (zh) * 2008-05-30 2012-11-14 日东电工株式会社 含有多奈哌齐的贴剂及其包装体
EP2343979B1 (en) 2008-10-08 2020-04-08 Agile Therapeutics, Inc. Transdermal delivery
EP2343963B1 (en) 2008-10-08 2019-04-10 Agile Therapeutics, Inc. Transdermal delivery
EP2343964A4 (en) 2008-10-08 2012-11-07 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
EP2387394B1 (en) * 2009-01-14 2018-05-02 Corium International, Inc. Transdermal administration of tamsulosin
WO2010111488A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
KR102093612B1 (ko) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
DE102010026883A1 (de) 2010-03-11 2011-12-15 Amw Gmbh Transdermales System mit Aromatasehemmer
EP2377540A1 (en) 2010-03-31 2011-10-19 Hexal AG Transdermal patch containing 17-deacetyl norgestimate
RU2445084C2 (ru) * 2010-04-27 2012-03-20 Государственное образовательное учреждение высшего профессионального образования Смоленская государственная медицинская академия федерального агентства по здравоохранению и социальному развитию Трансдермальный пластырь
DE102011100619A1 (de) 2010-05-05 2012-01-05 Amw Gmbh Transdermales therapeutisches System (TTS) mit einem Gehalt an einem Opiod-Analgetikum
DE102010026903A1 (de) 2010-07-12 2012-01-12 Amw Gmbh Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
FR2992325B1 (fr) 2012-06-26 2015-05-22 Ab7 Innovation Matrice sequencee multifonctionnelle monopolymerique en polyurethane coule et procede de fabrication
WO2014070958A1 (en) 2012-10-30 2014-05-08 Certirx Corporation Product, image, or document authentication, verification, and item identification
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
EP2821071A1 (en) 2013-07-04 2015-01-07 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for breast cancer treatment
WO2015007326A1 (en) 2013-07-18 2015-01-22 Institut D'investigació Biomèdica De Bellvitge (Idibell) Agents comprising a terminal alpha-galactosyl moiety for use in prevention and/or treatment of inflammatory diseases
KR20160055934A (ko) * 2013-10-07 2016-05-18 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물
RU2646512C2 (ru) * 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
RU2648449C2 (ru) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
KR101891186B1 (ko) * 2013-10-07 2018-08-24 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 포함하는 통증을 관리하기 위한 방법 및 조성물
KR101831290B1 (ko) 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
EP2930238A1 (en) 2014-04-09 2015-10-14 Fundacio Centre de Regulacio Genomica Compositions for treating cancer
EP2949324A1 (en) 2014-05-27 2015-12-02 Consorci Institut Catala de Ciencies Cardiovasculars Prevention and/or treatment of ischemia/reperfusion injury
EP2957634A1 (en) 2014-06-20 2015-12-23 Consejo Superior De Investigaciones Científicas Compounds for prevention and/or treatment of fibrotic diseases
EP2977463A1 (en) 2014-07-25 2016-01-27 Centro de Investigación Biomédica en Red (CIBER) Methods and agents related to lung diseases
EP2987503A1 (en) 2014-08-22 2016-02-24 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and reagents for prevention and/or treatment of infection
EP2997977A1 (en) 2014-09-19 2016-03-23 Fundación de la Comunidad Valenciana Centro de Investigación Principe Felipe Specific mtor inhibitors in the treatment of x-linked adrenoleukodystrophy
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3067369A1 (en) 2015-03-11 2016-09-14 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and compositions for the treatment of anti-angiogenic resistant cancer
EP3085366A1 (en) 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20180125860A1 (en) 2015-05-18 2018-05-10 Agile Therapeutics, Inc. Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3356384B1 (en) 2015-09-29 2023-11-29 Paris Sciences et Lettres Polypeptides comprising vinculin binding sites for the treatment of proliferation and/or adhesion related diseases
EP3219326A1 (en) 2016-03-14 2017-09-20 Institut Catalá De Ciencies Cardiovasculars (ICCC) Prevention and/or treatment of ischemia or ischemia/reperfusion injury
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
RU2723761C1 (ru) 2016-10-31 2020-06-17 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы устранения боли с использованием устройств для трансдермальной доставки дексмедетомидина
EP3556359A4 (en) 2016-12-19 2020-08-05 Nutritape, S.L. ENERGIZING PLASTER FOR SPORTS
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
WO2018162581A1 (en) 2017-03-07 2018-09-13 OP2 Drugs Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production
EP3385276A1 (en) 2017-04-03 2018-10-10 Targedys Proteins derived from clpb and uses thereof
EP3569228A1 (en) 2018-05-17 2019-11-20 Association pour la recherche à l'IGBMC (ARI) Non-steroidal selective glucocorticoid receptor agonistic modulators (segrams) and uses thereof
US20190151283A1 (en) 2017-10-27 2019-05-23 Association Pour La Recherche À L'igbmc (Ari) NON-STEROIDAL SELECTIVE GLUCOCORTICOID RECEPTOR AGONISTIC MODULATORS (SEGRAMs) AND USES THEREOF
EP3539975A1 (en) 2018-03-15 2019-09-18 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Micropeptides and uses thereof
WO2020033392A1 (en) * 2018-08-07 2020-02-13 Tedesco Erin Marie Hair extension device and method
CN113038969A (zh) 2018-09-06 2021-06-25 Op2药品公司 包含茴三硫或其衍生物的环糊精复合物的药物组合物
US20240358655A1 (en) * 2021-03-30 2024-10-31 Viatris Inc. Transdermal Systems having low dose estrogen and methods of making and use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE655916C (de) * 1934-03-04 1938-01-25 Mitteldeutsche Stahlwerke Akt Spurlager fuer Schleusentore
ATE95430T1 (de) * 1984-12-22 1993-10-15 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster.
DE3685895T2 (de) * 1985-02-25 1992-12-24 Univ Rutgers Dosierungssystem fuer transdermale absorption von arzneimittelwirkstoffen.
US5296230A (en) * 1985-02-25 1994-03-22 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4883669A (en) * 1985-02-25 1989-11-28 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration
CA1288698C (en) * 1985-08-30 1991-09-10 Yie W. Chien Transdermal anti-anginal pharmaceutical dosage
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
CN1021196C (zh) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
JPH0720866B2 (ja) * 1987-05-15 1995-03-08 三生製薬株式会社 エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤
US5422119A (en) * 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US4898920A (en) * 1987-10-15 1990-02-06 Dow Corning Corporation Adhesive compositions, controlled release compositions and transdermal delivery device
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5788983A (en) * 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
US5232707A (en) * 1989-07-10 1993-08-03 Syntex (U.S.A.) Inc. Solvent extraction process
US5252334A (en) † 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
US5508038A (en) * 1990-04-16 1996-04-16 Alza Corporation Polyisobutylene adhesives for transdermal devices
MY115126A (en) * 1990-04-27 2003-04-30 Seikisui Chemical Co Ltd Percutaneously absorbable eperisone or tolperisone preparation.
US5314694A (en) * 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
PT99338A (pt) * 1990-10-29 1992-10-30 Alza Corp Processo para a preparacao de composicoes de farmacos anticoncepcionais administradas transdermicamente contendo uma mistura dum estrogeno e gestodeno e dispositivos para a sua administracao transdermica
US5232702A (en) * 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
DE4210711A1 (de) † 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4229820C2 (de) * 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis
US5919478A (en) * 1993-06-25 1999-07-06 Alza Corporation Incorporating poly-N-vinyl amide in a transdermal system
DE4333595A1 (de) * 1993-10-01 1995-04-06 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Arzneimitteln auf die Haut
US5741511A (en) * 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
WO1996040087A2 (en) * 1995-06-07 1996-12-19 Cygnus, Inc. Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100355771C (zh) * 2003-06-30 2007-12-19 匈牙利吉瑞大药厂 合成高纯度D－(17α)－13－乙基－17－羟基－18,19－二去甲孕－4－烯－20－炔－3－酮－肟的方法
CN1318032C (zh) * 2005-01-24 2007-05-30 浙江大学 炔雌醇透皮吸收贴片
CN105416940A (zh) * 2015-11-30 2016-03-23 芜湖成德龙过滤设备有限公司 便于清洁的货架

Also Published As

Publication number Publication date
NO975586L (no) 1998-01-27
HU228434B1 (en) 2013-03-28
AU703593B2 (en) 1999-03-25
WO1996040355A1 (en) 1996-12-19
MX9709666A (es) 1998-10-31
HUP9802326A3 (en) 1999-07-28
AU6259796A (en) 1996-12-30
EP0836506A4 (en) 1999-05-26
US6071531A (en) 2000-06-06
EP0836506A1 (en) 1998-04-22
KR19990022722A (ko) 1999-03-25
DK0836506T3 (da) 2003-04-07
CN1188189C (zh) 2005-02-09
PL181582B1 (pl) 2001-08-31
CZ292151B6 (cs) 2003-08-13
JPH11501323A (ja) 1999-02-02
EP0836506B2 (en) 2011-12-21
DE69625483T3 (de) 2012-05-10
EP0836506B1 (en) 2002-12-18
US5972377A (en) 1999-10-26
PL323729A1 (en) 1998-04-14
IL122432A (en) 2000-07-16
ATE229828T1 (de) 2003-01-15
KR100301226B1 (ko) 2002-07-06
CA2222133C (en) 2002-12-24
CZ393297A3 (cs) 1999-06-16
US5876746A (en) 1999-03-02
PT836506E (pt) 2003-04-30
HUP9802326A2 (hu) 1999-02-01
DE69625483D1 (de) 2003-01-30
UA48973C2 (uk) 2002-09-16
ES2190472T5 (es) 2012-03-09
NZ311304A (en) 1999-03-29
DE69625483T2 (de) 2003-10-30
NO316308B1 (no) 2004-01-12
CA2222133A1 (en) 1996-12-19
JP2004043510A (ja) 2004-02-12
JP3534775B2 (ja) 2004-06-07
ES2190472T3 (es) 2003-08-01
NO975586D0 (no) 1997-12-03
DK0836506T4 (da) 2012-01-30
RU2177311C2 (ru) 2001-12-27
IL122432A0 (en) 1998-06-15

Similar Documents

Publication Publication Date Title
CN1188189C (zh) 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
US5693335A (en) Skin permeation enhancer composition for use with sex steroids
JP2579982B2 (ja) エストラジオール、その他のエストロゲンステロイドの経皮吸収投与ユニットと投与方法
AU652121B2 (en) Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
JPH09505554A (ja) 低フラックスで経皮的な活性薬剤の送達システム
US20210023092A1 (en) Transdermal Delivery
EP0737477A1 (en) Percutaneously absorbable preparation
EP2410859A1 (en) Transdermal delivery
US20080279915A1 (en) Matrix-Controlled Transdermal Therapeutic System Based on an Adhesive for Administering Norelgestromin or the Combination Thereof with an Estrogen
US20180104259A1 (en) Transdermal contraceptive hormones delivery
CN101843603B (zh) 无需渗透促进剂的激素透皮传递
CN1187042C (zh) 含甾族化合物的硬膏剂,其制备方法及其应用
EP1507538A1 (en) Norethindrone sustained release formulations and methods associated therewith
EP2377540A1 (en) Transdermal patch containing 17-deacetyl norgestimate
JPH04342531A (ja) 経皮吸収製剤
JPH04360828A (ja) 経皮吸収製剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: American New Jersey

Applicant after: 3-Dimensional Pharmaceuticals, Inc.

Address before: American California

Applicant before: Signus

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: CYGNUS INC. TO: AUTHOR-MAINAER PHARMACEUTICAL CORPORATION

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20050209

EXPY Termination of patent right or utility model